Fair and equitable access to COVID-19 treatments and vaccines

Policy Briefing

Published 29/05/2020

This rapid policy briefing highlights the key challenges for policy makers, regulatory bodies, industry, and research institutions to ensure fair and equitable access to a COVID-19 vaccine.

COVID vaccine smaller

COVID-19 research underway

There is a significant effort towards global collaboration for the development of tests, treatments, and vaccines for COVID-19. At present, there are over 200 authorised diagnostic tests to help detect COVID-19 and almost 100 drugs in human clinical trials. Research is underway investigating the possibilities of repurposing existing drugs to treat COVID-19. Different treatments in development include antiviral drugs, immunosuppressants/immunomodulators to modify or suppress the immune response, anti-inflammatory drugs, as well as cell and plasma-based therapies which use antibodies from the blood plasma of people who have recovered from COVID-19.

Alongside efforts to develop treatments for COVID-19, there are over 100 vaccines in the early or preclinical development phase and ten in clinical trials. No vaccines for other types of coronavirus (such as MERS-Cov or SARS-Cov) have been successfully developed and there is uncertainty concerning how long acquired immunity can last, with some evidence to suggest that immunity can be short-lived. Two out of every three candidate vaccines for infectious diseases usually fails, which means there are significant obstacles to overcome before an effective vaccine can be discovered and made available.

Share